Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What are the side effects of Wegovy?How does probenecid affect tigecycline's elimination?Does ginseng affect lipitor's effectiveness?Is Zegalogue a pre-filled syringe or an auto-injector?How does Sulbactam-Durlobactam treat pneumonia?
See the DrugPatentWatch profile for Radicava
Common Side Effects of Radicava Radicava, also known as edaravone, is a medication used to treat patients with amyotrophic lateral sclerosis (ALS). While generally well-tolerated, patients may experience certain side effects when taking Radicava. Infusion-Related Side Effects Radicava is administered intravenously over a 60-minute period. Some patients may experience infusion-related side effects, including headache, [1] fatigue, and swelling of the face, arms, and legs. [2] Nausea and Diarrhea About 10% to 20% of patients may experience nausea during or after treatment with Radicava. Diarrhea is also a common side effect, affecting approximately 15% of patients on the medication. [3] Other Side Effects Other reported side effects of Radicava include: - Increased risk of infections, such as pneumonia - Changes in blood pressure - Edema (swelling in the legs or face) - Abnormal results on liver or kidney function tests Why Are Patients and Healthcare Providers Concerned? While patients may initially respond to treatment with reduced symptoms, some patients have shown adverse effects in their clinical trial data. Edaravone (Radicava) is known to have a risk of exacerbating muscle weakness, a common symptom of ALS. What Steps Can Patients Take? To minimize the risk of side effects, patients should inform their healthcare providers of any pre-existing medical conditions and current medications. Monitoring vital signs and lab tests during and after treatment is essential. Sources: [1] https://www.drugpatentwatch.com/drug/edaravone [2] ClinicalTrials.gov: Edaravone for Amyotrophic Lateral Sclerosis (ALS) [3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208557Orig1s000lbl.pdf https://www.drugpatentwatch.com/drug/edaravone